Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaizhi Hewei Decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is specifically indicated for the treatment of non-erosive reflux disease (NERD), a subtype of gastroesophageal reflux disease (GERD), in patients presenting with the TCM syndrome of liver-stomach disharmony. Administered as granules, the decoction aims to improve clinical symptoms such as heartburn and acid regurgitation, enhance quality of life, and potentially reduce the reliance on proton pump inhibitors (PPIs). By addressing the underlying disharmony between the liver and stomach, the formula serves as an evidence-based TCM alternative to conventional therapies, particularly for patients experiencing side effects from PPI overuse.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chaizhi Hewei Decoction.